Niagen Bioscience, Inc. · NASDAQ:NAGE
Niagen Bioscience — Q1 2024 Earnings Presentation
19 slides from Niagen Bioscience's earnings presentation, May 8, 2024
Slide 1: ChromaDex Earnings Conference Call First Quarter 2024
ChromaDex Earnings Conference Call First Quarter 2024 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | May 8, 2024
Slide 2: Safe Harbor Statement
This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-
Slide 3: Q1 2024 & Recent Highlights
Q1 2024 & Recent Highlights • Total company and Tru Niagen® net sales of $22.2 million and $17.4 million, respectively. • Delivered solid gross margins of 60.7%, up 80 basis points YoY, compared to 59.9%. • Total sales and marketing expense improved as a percentage of net sales YoY (30.4% vs 34.9%).
Slide 4: Management Team
Management Team Rob Fried Brianna Gerber Chief Executive Officer Chief Financial Officer E-commerce & Over 20 years of diverse entertainment industry experience in investment executive management and finance at the Capital Group, Savoy Pictures, Columbia Mattel, and ChromaDex Pictures, Fried Films,
Slide 5: Financial Highlights
Financial Highlights 5 The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019)
Slide 6: Q1 2024 Net Sales Mix
Q1 2024 Net Sales Mix Q1 2024 Q1 2023 $22.2 MM $22.5 MM • Tru Niagen® net sales remained at 78% of net sales for Q1 2024 and Q1 2023(1) • Niagen®-related net sales increased to 97% of net sales in Q1 2024 compared to 95% in Q1 2023(2) Higher mix of Niagen®-related sales in Q1 2024 compared to the pr
Slide 7: Q1 2024 Net Sales
Q1 2024 Net Sales Q1 2024 Net Sales Growth Rates ($ in millions) YoY % (vs Q1 2023) +5% $17.4 (17)% +5% (11)% (100)% Total (2)% Tru Niagen® business down 2% year-over-year driven by lower Watson’s and Other B2B sales, partially offset by higher E-Commerce sales and Niagen® ingredient sales. 1. Other
Slide 8: 2022 – 2024 YTD Net Sales Summary
2022 – 2024 YTD Net Sales Summary ($ in millions) 2022 2023 2024 Description Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Q1 E-Commerce 10.9 12.0 11.3 11.1 45.3 12.2 13.0 12.7 13.3 51.2 12.9 Watsons 2.6 1.5 2.6 3.3 10.0 3.7 3.0 3.1 3.0 12.8 3.0 Other B2B 1.4 1.0 0.7 1.7 4.8 1.7 0.9 1.6 1.3 5.5 1.5 Total TRU NIAGEN
Slide 9: Q1 2024 vs Q1 2023 Key P&L Metrics
Q1 2024 vs Q1 2023 Key P&L Metrics (in thousands) Q1 2024 Q1 2023 Notes Tru Niagen® business down 2% as growth in e-commerce sales was Net Sales $22,153 $22,556 offset by lower Watson’s and other distributor partner sales, primarily driven by timing of sales. Gross Profit 13,456 13,518 Up 80bps prim
Slide 10: Adjusted EBITDA Summary
Adjusted EBITDA Summary ChromaDex Corporation and Subsidiaries Reconciliation of Non-GAAP Finanical Measures (In thousands) Three months ended Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Net loss, as reported $ (7,740) $ (6,397) $ (985) $ (1,418) $ (1,902) $ (2,191) $ (95
Slide 11: Q1 2024 Operating Loss vs Q1 2023
Q1 2024 Operating Loss vs Q1 2023 +$2.4 MM -$1.1 MM (in millions) 11
Slide 12: Quarterly Balance Sheet Highlights
Quarterly Balance Sheet Highlights (in thousands) 12/31/21 12/31/22 3/31/23 6/30/23 9/30/23 12/31/23 3/31/24 Key Drivers (Q4 2023 vs Q1 2024) Up $0.2 million driven by cash provided from Cash $28,219 $20,441 $23,141 $26,406 $26,773 $27,325 $27,565 operations Down $2.0 million driven by timing of Inv
Slide 13: Quarterly Cash Flow Highlights
Quarterly Cash Flow Highlights (in thousands) FY 2021 FY 2022 3/31/23 6/30/23 9/30/23 12/31/2023 FY 2023 3/31/24 Net Loss $(27,128) $(16,540) (2) $(1,902) $(2,191) $(959) $114 $(4,938) $(492) Working Capital (4,915) (5,927) (2) 2,644 3,401 (422) (417) 5,206 (643) Cash From / (Used for) Operations (2
Slide 14: 2024 Financial Outlook
2024 Financial Outlook (in thousands) 2022 Actual 2023 Actual 2024 Full Year Outlook Key Drivers • Includes growth from e-commerce business and Higher YoY growth compared to FY 2023 recurring revenues from established Net Sales $72,050 $83,570 growth of +16% partnerships (unchanged from last quarter
Slide 15: The Science
The Science 15 The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019)
Slide 16: Science Continues to Expand
Science Continues to Expand • Two new human trials on nicotinamide riboside registered since prior update:¹ ▪ The University of Texas Health Science Center, Houston (February 2024) • The objective is to determine whether NR decreases glucose uptake in the aorta of patients with smooth muscle dysfunc
Slide 17: Scientific Advisory Board
Scientific Advisory Board NOBEL PRIZE WINNERS | CHEMISTRY Charles Brenner, Ph.D. Roger Kornberg, Ph.D. Rudolph Tanzi, Ph.D. Alfred E Mann Family Chairman Kennedy Professor of Foundation Chair, Professor of Structural Neurology Department of Diabetes & Biology Harvard University Cancer Metabolism Sta
Slide 18: Clinical Studies on Niagen® in Multiple Health Areas
Clinical Studies on Niagen® in Multiple Health Areas Note: highlighted achievements in duration, participation and dosage only consider completed studies. (As of April 24, 2024) 18
Slide 19: Contact Info
Contact Info: Ben Shamsian Lytham Partners T: +1(646) 829-9701 Shamsian@LythamPartners.com www.ChromaDex.com Where to buy Tru Niagen® TruNiagen.com Amazon.com The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be